<DOC>
	<DOCNO>NCT03103295</DOCNO>
	<brief_summary>This study investigate safety efficacy traumatic bone defect treatment use 3D tissue engineer bone equivalent ( 3D-TEBE ) . The aim study evaluate 3D-TEBE transplantation safe efficient treatment patient traumatic long bone defect critical size .</brief_summary>
	<brief_title>3D Tissue Engineered Bone Equivalent Treatment Traumatic Bone Defects</brief_title>
	<detailed_description>This new method critical size long bone defect treatment clinical development . Treatment critical size bone defect actual clinical challenge . The `` gold standard '' case autologous bone grafting . The method disadvantage associate limited donor bone resource . Based preliminary clinical trial positive result use autologous culture bone marrow-derived multipotent mesenchymal stromal cell ( BM-MSCs ) traumatology , aim develop 3D tissue-engineered bone equivalent transplantation technology restoration critical size bone defect . The propose 3D-TEBE transplantation bone defect critical size treatment expect restore bone integrity , form new bone tissue site bone defect , reduce rehabilitation period patient . The data obtain study practical implication treatment reparative osteogenesis alteration base principle evidence-based medicine</detailed_description>
	<criteria>Age 18 60 year Patients long bone defect critical size traumatic genesis ; Lack consolidation bone fragment least 9 month ; At least two attempt achieve bone consolidation use traditional method treatment ; A negative pregnancy test woman childbearing age ; Confirmation participation study sign The Written Informed Consent , personally responsible caretaker ; The infection area bone defect ; History prior cancer ; Diabetes ; Severe chronic liver disease kidneys disease history Pregnancy ; The presence vascular , endocrine somatic pathology direct impact osteoreparation ; Any physical disease decompensation subcompensation , rat severe moderate ; Therapeutic issue psychiatric disorder patient would make subject unsuitable participate study complete ; Participation another clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>tissue engineering ,</keyword>
	<keyword>regeneration ,</keyword>
	<keyword>repair ,</keyword>
	<keyword>traumatic bone defect ,</keyword>
	<keyword>regenerative therapy</keyword>
</DOC>